ADT1140-CMB-401 Biosimilar-Anti-MUC1/CD227 mAb-Research Grade
- +1 609-736-0910
- info@alphalifetech.com
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1140 |
Product Name |
ADT1140-CMB-401 Biosimilar-Anti-MUC1/CD227 mAb-Research Grade |
Clonity |
Monoclonal |
|
Alternate Names anti-mouse cd227 antibody, anti-cd227 antibody, anti cd227 antibody, recombinant cd227, muc1 antibody, anti-cd227 monoclonal antibody, cd227 antibodies, cd227 recombinant antibody, cd227 blocking antibody |
|
Alias |
hPAM4, hPAM4 IgG-DOTA, hPAM4-DOTA |
Host |
CHO Cells |
Species |
Human |
Target |
MUC1/CD227 |
Gene ID |
4582 |
Isotype |
IgG1 Kappa |
Size |
100ug, 1mg, 5mg |
Research Area |
Cancer |
CAS Number |
1462876-11-4 |
Product Description |
Yttrium (90Y) clivatuzumab tetraxetan (trade name hPAM4-Cide) is a humanized monoclonal antibody-drug conjugate designed for the treatment of pancreatic cancer. The antibody part, clivatuzumab (targeted at MUC1), is conjugated with tetraxetan, a chelator for yttrium-90, a radioisotope which destroys the tumour cells. |
Application |
ELISA, WB |
Purity |
>95% as determined by SDS-PAGE |
Concentration |
batch dependent |
Buffer |
Supplied in PBS, PH7.5 |
Storage |
Store at -20 °C for 12 months. Store at -80 °C for long term storage. |
Shipping Condition |
Shipped on ice packs. |
Note |
This product is for research use only. |
Reference |
1. Azekawa S, et al. BMJ Open Respir Res, 2023 May. PMID 37230764
2. de Haan A, et al. Kidney Int, 2023 May. PMID 37085259
3. Lucarelli G, et al. Int J Mol Sci, 2023 Mar 2. PMID 36902242
|